1887

Abstract

With the human immunodeficiency virus type 1 (HIV-1) epidemic expanding at increasing speed, development of a safe and effective vaccine remains a high priority. One of the most central vaccine platforms considered is plasmid DNA. However, high doses of DNA and several immunizations are typically needed to achieve detectable T-cell responses. In this study, a Semliki Forest virus replicon DNA vaccine designed for human clinical trials, DREP.HIVA, encoding an antigen that is currently being used in human trials in the context of a conventional DNA plasmid, pTHr.HIVA, was generated. It was shown that a single immunization of DREP.HIVA stimulated HIV-1-specific T-cell responses in mice, suggesting that the poor immunogenicity of conventional DNA vaccines may be enhanced by using viral replicon-based plasmid systems. The results presented here support the evaluation of Semliki Forest virus replicon DNA vaccines in non-human primates and in clinical studies.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.80481-0
2005-02-01
2019-12-06
Loading full text...

Full text loading...

/deliver/fulltext/jgv/86/2/vir860349.html?itemId=/content/journal/jgv/10.1099/vir.0.80481-0&mimeType=html&fmt=ahah

References

  1. Anraku, I., Harvey, T. J., Linedale, R., Gardner, J., Harrich, D., Suhrbier, A. & Khromykh, A. A. ( 2002; ). Kunjin virus replicon vaccine vectors induce protective CD8+ T-cell immunity. J Virol 76, 3791–3799.[CrossRef]
    [Google Scholar]
  2. Barouch, D. H., Santra, S., Schmitz, J. E. & 26 other authors ( 2000; ). Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290, 486–492.[CrossRef]
    [Google Scholar]
  3. Barouch, D. H., McKay, P. F., Sumida, S. M. & 8 other authors ( 2003; ). Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J Virol 77, 8729–8735.[CrossRef]
    [Google Scholar]
  4. Been, M. D., Perrotta, A. T. & Rosenstein, S. P. ( 1992; ). Secondary structure of the self-cleaving RNA of hepatitis delta virus: applications to catalytic RNA design. Biochemistry 31, 11843–11852.[CrossRef]
    [Google Scholar]
  5. Berglund, P., Smerdou, C., Fleeton, M. N., Tubulekas, I. & Liljestrom, P. ( 1998; ). Enhancing immune responses using suicidal DNA vaccines. Nat Biotechnol 16, 562–565.[CrossRef]
    [Google Scholar]
  6. Berglund, P., Fleeton, M. N., Smerdou, C. & Liljestrom, P. ( 1999; ). Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice. Vaccine 17, 497–507.[CrossRef]
    [Google Scholar]
  7. Chen, D., Endres, R., Maa, Y. F., Kensil, C. R., Whitaker-Dowling, P., Trichel, A., Youngner, J. S. & Payne, L. G. ( 2003; ). Epidermal powder immunization of mice and monkeys with an influenza vaccine. Vaccine 21, 2830–2836.[CrossRef]
    [Google Scholar]
  8. Cranenburgh, R. M., Hanak, J. A., Williams, S. G. & Sherratt, D. J. ( 2001; ). Escherichia coli strains that allow antibiotic-free plasmid selection and maintenance by repressor titration. Nucleic Acids Res 29, E26.[CrossRef]
    [Google Scholar]
  9. Dubensky, T. W., Jr, Driver, D. A., Polo, J. M. & 9 other authors ( 1996; ). Sindbis virus DNA-based expression vectors: utility for in vitro and in vivo gene transfer. J Virol 70, 508–519.
    [Google Scholar]
  10. Fleeton, M. N., Chen, M., Berglund, P., Rhodes, G., Parker, S. E., Murphy, M., Atkins, G. J. & Liljestrom, P. ( 2001; ). Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus. J Infect Dis 183, 1395–1398.[CrossRef]
    [Google Scholar]
  11. Hanke, T. & McMichael, A. J. ( 2000; ). Design and construction of an experimental HIV-1 vaccine for a year – 2000 clinical trial in Kenya. Nat Med 6, 951–955.[CrossRef]
    [Google Scholar]
  12. Hanke, T., Schneider, J., Gilbert, S. C., Hill, A. V. & McMichael, A. ( 1998; ). DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice. Vaccine 16, 426–435.[CrossRef]
    [Google Scholar]
  13. Hanke, T., Barnfield, C., Wee, E. G., Agren, L., Samuel, R. V., Larke, N. & Liljestrom, P. ( 2003; ). Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine. J Gen Virol 84, 361–368.[CrossRef]
    [Google Scholar]
  14. Hariharan, M. J., Driver, D. A., Townsend, K. & 11 other authors ( 1998; ). DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. J Virol 72, 950–958.
    [Google Scholar]
  15. Kariko, K., Ni, H., Capodici, J., Lamphier, M. & Weissman, D. ( 2004; ). mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem 279, 12542–12550.[CrossRef]
    [Google Scholar]
  16. Karlsson, G. B. & Liljestrom, P. ( 2004; ). Delivery and expression of heterologous genes in mammalian cells using self-replicating alphavirus vectors. Methods Mol Biol 246, 543–557.
    [Google Scholar]
  17. Kirman, J. R., Turon, T., Su, H., Li, A., Kraus, C., Polo, J. M., Belisle, J., Morris, S. & Seder, R. A. ( 2003; ). Enhanced immunogenicity to Mycobacterium tuberculosis by vaccination with an alphavirus plasmid replicon expressing antigen 85A. Infect Immun 71, 575–579.[CrossRef]
    [Google Scholar]
  18. Leitner, W. W., Ying, H., Driver, D. A., Dubensky, T. W. & Restifo, N. P. ( 2000; ). Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. Cancer Res 60, 51–55.
    [Google Scholar]
  19. Leitner, W. W., Hwang, L. N., deVeer, M. J., Zhou, A., Silverman, R. H., Williams, B. R., Dubensky, T. W., Ying, H. & Restifo, N. P. ( 2003; ). Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med 9, 33–39.
    [Google Scholar]
  20. Leitner, W. W., Hwang, L. N., Bergmann-Leitner, E. S., Finkelstein, S. E., Frank, S. & Restifo, N. P. ( 2004; ). Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines. Vaccine 22, 1537–1544.[CrossRef]
    [Google Scholar]
  21. McKeever, U., Barman, S., Hao, T., Chambers, P., Song, S., Lunsford, L., Hsu, Y.-Y., Roy, K. & Hedley, M. L. ( 2002; ). Protective immune responses elicited in mice by immunization with formulations of poly(lactide-co-glycolide) microparticles. Vaccine 20, 1524–1531.[CrossRef]
    [Google Scholar]
  22. Morris-Downes, M. M., Phenix, K. V., Smyth, J., Sheahan, B. J., Lileqvist, S., Mooney, D. A., Liljestrom, P., Todd, D. & Atkins, G. J. ( 2001a; ). Semliki Forest virus-based vaccines: persistence, distribution and pathological analysis in two animal systems. Vaccine 19, 1978–1988.[CrossRef]
    [Google Scholar]
  23. Morris-Downes, M. M., Sheahan, B. J., Fleeton, M. N., Liljestrom, P., Reid, H. W. & Atkins, G. J. ( 2001b; ). A recombinant Semliki Forest virus particle vaccine encoding the prME and NS1 proteins of louping ill virus is effective in a sheep challenge model. Vaccine 19, 3877–3884.[CrossRef]
    [Google Scholar]
  24. Mossman, S. P., Bex, F., Berglund, P. & 11 other authors ( 1996; ). Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine. J Virol 70, 1953–1960.
    [Google Scholar]
  25. Mwau, M., Cebere, I., Sutton, J. & 16 other authors ( 2004; ). A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 85, 911–919.[CrossRef]
    [Google Scholar]
  26. Perrotta, A. T. & Been, M. D. ( 1991; ). A pseudoknot-like structure required for efficient self-cleavage of hepatitis delta virus RNA. Nature 350, 434–436.[CrossRef]
    [Google Scholar]
  27. Racanelli, V., Behrens, S. E., Aliberti, J. & Rehermann, B. ( 2004; ). Dendritic cells transfected with cytopathic self-replicating RNA induce crosspriming of CD8+ T cells and antiviral immunity. Immunity 20, 47–58.[CrossRef]
    [Google Scholar]
  28. SenGupta, D., Norris, P. J., Suscovich, T. J. & 10 other authors ( 2004; ). Heat shock protein-mediated cross-presentation of exogenous HIV antigen on HLA class I and class II. J Immunol 173, 1987–1993.[CrossRef]
    [Google Scholar]
  29. Shi, Y., Evans, J. E. & Rock, K. L. ( 2003; ). Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425, 516–521.[CrossRef]
    [Google Scholar]
  30. Takahashi, H., Cohen, J., Hosmalin, A. & 7 other authors ( 1988; ). An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 85, 3105–3109.[CrossRef]
    [Google Scholar]
  31. Williams, S. G., Cranenburgh, R. M., Weiss, A. M., Wrighton, C. J., Sherratt, D. J. & Hanak, J. A. ( 1998; ). Repressor titration: a novel system for selection and stable maintenance of recombinant plasmids. Nucleic Acids Res 26, 2120–2124.[CrossRef]
    [Google Scholar]
  32. Yamanaka, R. & Xanthopoulos, K. G. ( 2004; ). Development of improved Sindbis virus-based DNA expression vector. DNA Cell Biol 23, 75–80.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.80481-0
Loading
/content/journal/jgv/10.1099/vir.0.80481-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error